<DOC>
	<DOCNO>NCT01642940</DOCNO>
	<brief_summary>This prospective , randomize , single-center , single blind , investigator initiate , two period study crossover design . Diabetic patient Acute Coronary Syndrome ( ACS ) , treat oral and/or parenteral hypoglycaemic therapy least 1 month subject percutaneous coronary intervention ( PCI ) , randomize baseline platelet reactivity ( PR ) assessment ( 24 hour post PCI ) clopidogrel 1:1 ratio either prasugrel 10mg ticagrelor 180mg 15 day follow crossover directly alternate therapy additional 15 day without intervene washout period .</brief_summary>
	<brief_title>Τicagrelor Versus Prasugrel Diabetic Patients : Pharmacodynamic Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Age 18 75 year Diabetic patient treat oral and/or parenteral hypoglycaemic therapy least 1 month Patients acute coronary syndrome subject PCI baseline PR evaluation 24 hour post PCI clopidogrel Informed consent obtain write Treatment investigational agent ( include placebo ) device within 30 day prior randomization plan use investigational agent device prior Day 30 visit . Pregnancy Breastfeeding Inability give inform consent high likelihood unavailable Day 30 follow . Cardiogenic shock Major periprocedural complication ( death , stent thrombosis , vessel perforation , arrhythmia require cardioversion , temporary pacemaker insertion intravenous antiarrhythmic agent , respiratory failure require intubation , vascular injury ( pseudoaneurysm , arteriovenous shunt , retroperitoneal bleed hematoma &gt; 5 cm arterial catheter insertion site ) , major bleeding ( need bood transfusion drop haemoglobin postPCI ≥ 5 gr/ dl intracranial bleeding ) . Unsuccessful PCI ( residual stenosis &gt; 30 % flow &lt; ΤΙΜΙ 3 ) plan stag PCI next 30 day randomization Requirement oral anticoagulant prior Day 30 visit Current plan therapy thienopyridine class ADP receptor inhibitor . Known hypersensitivity prasugrel ticagrelor History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 6 month . Other bleed diathesis , consider investigator high risk bleed longterm thienopyridine therapy . Any previous history ischemic stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . Thrombocytopenia ( &lt; 100.000/μL ) randomization Anaemia ( Hct &lt; 30 % ) randomization Polycytaemia ( Hct &gt; 52 % ) randomization Periprocedural IIb/IIIa inhibitor administration Severe allergy contrast agent , unfractionated heparin , enoxaparin bivalirudin adequately premedicated . Recent ( &lt; 6 week ) major surgery trauma , include GABG . Subjects receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study . Concomitant oral IV therapy strong CY P3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazana vir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3A inducer ( rifampin /rifampicin , phenytoin , carbamazepine ) . Increased risk bradycardiac event . Dialysis require . Age ≥ 75 year Weight &lt; 60 Kg Severe hepatic impairment Severe uncontrolled chronic obstructive pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>